Johnson & Johnson (JNJ) May be Poised for Growth  
12/17/2012 7:13:12 AM

Johnson & Johnson (JNJ.N) may be set to deliver mid single-digit revenue growth and high single-digit profit growth in the next few years, lead by its pharmaceutical division, according to an article in Barron's. The growth could come after years of large missteps, including factory problems in its Consumer Division and a $2.9 billion charge related to the recall of artificial hips, Barron's said in its December 17 edition. "Revenue growth is improving in all three businesses," Barclays analyst C. Anthony Butler told Barron's.